Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record
Paradigm Biopharmaceuticals ("Paradigm"), a global biopharmaceutical company specializing in repurposing existing drugs for unmet medical needs, announced their retention of Rubenstein Public Relations (RPR) as its agency of record.
RPR will provide counsel to Paradigm on their corporate messaging and guide the development of their brand positioning in both the U.S. and global markets.
"We are excited to begin our partnership with RPR, as their firm is well-equipped to guide our company across the U.S. media landscape and highlight our innovative therapies which have the potential to enhance the quality of life of millions," said Paradigm CMO and Interim CEO, Dr. Donna Skerrett.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
